Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • ID: 4613269
  • Report
  • Region: Asia Pacific
  • 152 Pages
  • GBI Research
1 of 5
Colorectal Cancer (CRC) is the Most Common Cancer and the Leading Cause of Cancer-Related Mortality Globally, Accounting for 0.77 Million Deaths in 2015.

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Eli Lilly
  • Jiangsu Chia-Tai Tianqing
  • Merck KGaA
  • Regeneron
  • MORE

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 50 and over, a high-risk age range for Colorectal Cancer (CRC). Over half of the incident cases of Colorectal Cancer (CRC) are diagnosed in patients over the age of 50. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally, accounting for 0.77 million deaths in 2015.

The five-year prevalence population for Colorectal Cancer (CRC) in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles. However, growing awareness of the disease and associated risk factors together with the availability of free testing services for Colorectal Cancer (CRC) patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly.

On the other hand, the poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The Colorectal Cancer (CRC) market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.

The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" details the key points (etiology, epidemiology, current treatment, products currently marketed and in pipeline, market drivers and barriers) driving the Colorectal Cancer (CRC) market in the five Asia-Pacific (APAC) markets: India, China, Australia, South Korea and Japan.

Scope

  • The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
  • How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?
  • The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
  • What implications will the increased focus on targeted therapies have on the future of CRC treatment?
  • Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
  • The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, obesity and lifestyle influence the market?
  • Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Bayer
  • Eli Lilly
  • Jiangsu Chia-Tai Tianqing
  • Merck KGaA
  • Regeneron
  • MORE

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
    2.4.1 Etiology
    2.4.2 Pathophysiology
    2.4.3 Biomarkers/Targets of Interest
2.5 Diagnosis
    2.5.1 Digital Rectal Examination
    2.5.2 Fecal Occult Blood Test
    2.5.3 Flexible Sigmoidoscopy
    2.5.4 Colonoscopy
    2.5.5 Virtual Colonoscopy
    2.5.6 Double Contrast Barium Enema
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Guidelines and Options
    2.8.1 Surgery and Radiation Therapy
    2.8.2 Chemotherapy
    2.8.3 Targeted Therapies
    2.8.4 Resistance to Pharmacological Therapies
    2.8.5 Treatment Algorithm

3 Marketed Products

3.1 Overview
3.2 Chemotherapies
    3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma
    3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma
    3.2.3 UFT (tegafur plus uracil) - Merck KGaA
3.3 Epidermal Growth Factor Receptor Targeted Therapies
    3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA
    3.3.2 Vectibix (panitumumab) - Amgen/Takeda
3.4 Anti-angiogenesis Therapies
    3.4.1 Avastin (bevacizumab) - Roche
    3.4.2 Cyramza (ramucirumab) - Eli Lilly
    3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron
3.5 Kinase Inhibitors
    3.5.1 Stivarga (regorafenib) - Bayer/Onyx
3.6 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis

4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
    4.4.1 Keytruda (pembrolizumab) - Merck & Co.
    4.4.2 Opdivo (nivolumab) - Bristol-Myers Squib
    4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma
    4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma
    4.4.5 Fruquintinib (HMPL-013) - Hutchison MediPharma
    4.4.6 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
    4.4.7 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
    4.4.8 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis

5.1 Failure Rate
    5.1.1 Overall Failure Rate
    5.1.2 Failure Rate by Phase and Molecule Type
    5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
    5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
    5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
    5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
    5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
    5.3.1 Trial Duration by Molecule Type and Stage of Development
    5.3.2 Trial Duration by Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics

6 Multi-scenario Forecast

6.1 Overview
6.2 Asia-Pacific Market
6.3 India
    6.3.1 Treatment Usage Patterns
    6.3.2 Annual Cost of Therapy
    6.3.3 Market Size
6.4 China
    6.4.1 Treatment Usage Patterns
    6.4.2 Annual Cost of Therapy
    6.4.3 Market Size
6.5 Australia
    6.5.1 Treatment Usage Patterns
    6.5.2 Annual Cost of Therapy
    6.5.3 Market Size
6.6 South Korea
    6.6.1 Treatment Usage Patterns
    6.6.2 Annual Cost of Therapy
    6.6.3 Market Size
6.7 Japan
    6.7.1 Treatment Usage Patterns
    6.7.2 Annual Cost of Therapy
    6.7.3 Market Size

7 Drivers and Barriers

7.1 Drivers
    7.1.1 Increasing Elderly Population and Incidence of CRC
    7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate
    7.1.3 Increase in Mutation Testing to Drive Market Growth
    7.1.4 Availability of Novel First-, Second- and Third-Line Therapy Options in Pipeline
    7.1.5 Diversified Healthcare Reform to Boost Market Growth
    7.1.6 Diversified Health Insurance System to Help Nurture Growth
7.2 Barriers
    7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth
    7.2.2 High Prices of Therapeutics to Slow Down Market Growth
    7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm
    7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products
    7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
    7.2.6 Drug Pricing Reforms

8 Deals and Strategic Consolidations

8.1 Licensing Deals
    8.1.1 Deals by Region and Value
    8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
    8.1.4 Key Licensing Deals
8.2 Co-development Deals
    8.2.1 Deals by Region and Value
    8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
    8.2.4 Key Co-development Deals

9 Appendix

List of Tables

Table 1: CRC Therapeutics Market, Symptoms of CRC
Table 2: CRC Therapeutics Market, Stage Definitions for CRC
Table 3: CRC Therapeutics Market, Prognosis for CRC
Table 4 CRC Therapeutics, Surgical Options for CRC
Table 5: CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2007-2018
Table 6: CRC Therapeutics Market, Global, Co-development Deals Value, 2007-2018
Table 7: CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
Table 8: CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
Table 9: CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2018
Table 10: CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
Table 11: CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
Table 12: CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
Table 13: CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018
Table 14: CRC Therapeutics Market, APAC, Market Forecast, 2017-2024
Table 15: CRC Therapeutics Market, India, Market Forecast, 2017-2024
Table 16: CRC Therapeutics Market, China, Market Forecast, 2017-2024
Table 17: CRC Therapeutics Market, Australia, Market Forecast, 2017-2024
Table 18: CRC Therapeutics Market, South Korea, Market Forecast, 2017-2024
Table 19: CRC Therapeutics Market, Japan, Market Forecast, 2017-2024

List of Figures

Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013
Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC
Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products, 2018
Figure 4: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for First-line Marketed Products, 2018
Figure 5: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Second-line Marketed Products, 2018
Figure 6: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Third or Fourth-line Marketed Products, 2018
Figure 7: CRC Therapeutics Market, Global, Pipeline, 2018
Figure 8: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2018
Figure 9: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2018
Figure 10: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2020-2024
Figure 11: CRC Therapeutics Market, APAC, Opdivo Forecast ($m), 2023-2024
Figure 12: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2022-2024
Figure 13: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021-2024
Figure 14: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018-2024
Figure 15: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2021-2024
Figure 16: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020-2024
Figure 17: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021-2024
Figure 18: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products, 2018
Figure 19: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline Products, 2018
Figure 20: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017
Figure 21: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017
Figure 22: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017
Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017
Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017
Figure 25: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017
Figure 26: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017
Figure 27: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017
Figure 28: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017
Figure 29: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 30: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 31: CRC Therapeutics Market, APAC, Treatment Patterns (‘000), 2017-2024
Figure 32: CRC Therapeutics Market, APAC, Market Size ($bn), 2017-2024
Figure 33: CRC Therapeutics Market, India, Treatment Patterns (‘000), 2017-2024
Figure 34: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024
Figure 35: CRC Therapeutics Market, India, Market Size ($m), 2017-2024
Figure 36: CRC Therapeutics Market, China, Treatment Patterns (‘000), 2017-2024
Figure 37: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024
Figure 38: CRC Therapeutics Market, China, Market Size ($bn), 2017-2024
Figure 39: CRC Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024
Figure 40: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024
Figure 41: CRC Therapeutics Market, Australia, Market Size ($m), 2017-2024
Figure 42: CRC Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024
Figure 43: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
Figure 44: CRC Therapeutics Market, South Korea, Market Size ($m), 2017-2024
Figure 45: CRC Therapeutics Market, Japan, Treatment Patterns (‘000), 2017-2024
Figure 46: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024
Figure 47: CRC Therapeutics Market, Japan, Market Size ($bn), 2017-2024
Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018
Figure 49: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018
Figure 50: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
Figure 51: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018
Figure 52: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018
Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018
Figure 54: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018
Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
Figure 56: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2007-2018
Figure 57: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Taiho Pharma
  • Merck KGaA
  • Amgen
  • Takeda
  • Roche
  • Eli Lilly
  • Sanofi
  • Regeneron
  • Bayer
  • Onyx
  • Bristol-Myers Squib
  • Sumitomo Dainippon Pharma
  • Array BioPharma
  • Hutchison MediPharma
  • Jiangsu Hengrui Medicine
  • Jiangsu Chia-Tai Tianqing
  • Suzhou Zelgen Biopharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll